| Source: |
| Type: |
| Enzymes involved in regulating gene expression by removing acetyl groups from histones, the proteins around which DNA is wrapped. -Many cancers exhibit altered expression levels of HDACs, which can contribute to the dysregulation of genes involved in cell growth, survival, and differentiation. -HDACs can repress the expression of tumor suppressor genes, leading to uncontrolled cell proliferation and survival. This repression can be a key factor in the development and progression of cancer. -HDAC inhibitors (HDACi) have been developed and are being investigated for their ability to reactivate silenced genes, induce cell cycle arrest, and promote apoptosis in cancer cells. -HDAC1, HDAC2): Often overexpressed in various cancers, including breast, prostate, and colorectal cancers. Their overexpression is associated with poor prognosis. -HDAC4, HDAC5): These may have both oncogenic and tumor-suppressive roles depending on the context and cancer type. -While HDACs are not classified as traditional oncogenes, their overexpression and activity can contribute to oncogenic processes. -HDAC inhibitor works by preventing the removal of acetyl groups from histones, thereby modulating gene expression, influencing cell behavior, and potentially reversing aberrant gene silencing seen in various diseases. -HDAC inhibitors can help reactivate these genes, thereby inhibiting growth and inducing apoptosis in cancer cells. |
| 3193- | SFN, | Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress |
| - | Review, | Var, | NA |
| 3192- | SFN, | Transcriptome analysis reveals a dynamic and differential transcriptional response to sulforaphane in normal and prostate cancer cells and suggests a role for Sp1 in chemoprevention |
| - | in-vitro, | Pca, | PC3 |
| 3660- | SFN, | Sulforaphane - role in aging and neurodegeneration |
| - | Review, | AD, | NA |
| 1061- | SFN, | Relevance of the natural HDAC inhibitor sulforaphane as a chemopreventive agent in urologic tumors |
| - | vitro+vivo, | NA, | NA |
| - | in-vitro, | Pca, | NA |
| 2555- | SFN, | Chemopreventive functions of sulforaphane: A potent inducer of antioxidant enzymes and apoptosis |
| - | Review, | Var, | NA |
| 2556- | SFN, | The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review |
| - | Review, | Var, | NA |
| 2554- | SFN, | Sulforaphane (SFN): An Isothiocyanate in a Cancer Chemoprevention Paradigm |
| - | Review, | Var, | NA |
| 2448- | SFN, | Sulforaphane and bladder cancer: a potential novel antitumor compound |
| - | Review, | Bladder, | NA |
| 1730- | SFN, | Sulforaphane: An emergent anti-cancer stem cell agent |
| - | Review, | Var, | NA |
| 1725- | SFN, | Anticancer Activity of Sulforaphane: The Epigenetic Mechanisms and the Nrf2 Signaling Pathway |
| - | Review, | Var, | NA |
| 1724- | SFN, | Sulforaphane: A review of its therapeutic potentials, advances in its nanodelivery, recent patents, and clinical trials |
| - | Review, | Var, | NA |
| 1722- | SFN, | Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems |
| - | Review, | Var, | NA |
| 1428- | SFN, | Broccoli or Sulforaphane: Is It the Source or Dose That Matters? |
| - | Review, | NA, | NA |
| 1458- | SFN, | Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma |
| - | Review, | Bladder, | NA |
| 1454- | SFN, | Absorption and chemopreventive targets of sulforaphane in humans following consumption of broccoli sprouts or a myrosinase-treated broccoli sprout extract |
| - | Human, | Nor, | NA |
| 1453- | SFN, | Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7 |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 1452- | SFN, | Sulforaphane Suppresses the Nicotine-Induced Expression of the Matrix Metalloproteinase-9 via Inhibiting ROS-Mediated AP-1 and NF-κB Signaling in Human Gastric Cancer Cells |
| - | in-vitro, | GC, | AGS |
| 1437- | SFN, | Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition |
| - | Review, | NA, | NA |
| 1434- | SFN, | GEM, | Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity |
| - | in-vitro, | CCA, | HuCCT1 | - | in-vitro, | CCA, | HuH28 | - | in-vivo, | NA, | NA |
| 1508- | SFN, | Nrf2 targeting by sulforaphane: A potential therapy for cancer treatment |
| - | Review, | Var, | NA |
| 1507- | SFN, | Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects |
| - | in-vivo, | Colon, | NA | - | Human, | Nor, | NA |
| 1502- | SFN, | Epigenetic targets of bioactive dietary components for cancer prevention and therapy |
| - | Review, | NA, | NA |
| 1500- | SFN, | A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase |
| - | in-vitro, | Nor, | HEK293 | - | in-vitro, | CRC, | HCT116 |
| 1430- | SFN, | Sulforaphane bioavailability and chemopreventive activity in women scheduled for breast biopsy |
| - | Trial, | BC, | NA |
| 1497- | SFN, | Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells |
| - | in-vitro, | Nor, | PrEC | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 1496- | SFN, | VitD3, | Association between histone deacetylase activity and vitamin D-dependent gene expressions in relation to sulforaphane in human colorectal cancer cells |
| - | in-vitro, | CRC, | Caco-2 |
| 1494- | SFN, | doxoR, | Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model |
| - | in-vivo, | BC, | NA | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| 1484- | SFN, | Sulforaphane’s Multifaceted Potential: From Neuroprotection to Anticancer Action |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 |
| 3288- | SIL, | Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations |
| - | Review, | Var, | NA |
| 3282- | SIL, | Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions |
| - | Review, | NA, | NA |
| 1062- | SSE, | Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | T98G | - | in-vitro, | GBM, | U87MG |
| 2353- | TQ, | The effects of thymoquinone on pancreatic cancer: Evidence from preclinical studies |
| - | Review, | PC, | NA |
| 2119- | TQ, | Dual properties of Nigella Sativa: anti-oxidant and pro-oxidant |
| - | Review, | Var, | NA |
| 2100- | TQ, | Dual properties of Nigella Sative: Anti-oxidant and Pro-oxidant |
| - | Review, | NA, | NA |
| 2101- | TQ, | HDAC inhibition by Nigella sativa L. sprouts extract in hepatocellular carcinoma: an approach to study anti-cancer potential |
| - | Study, | HCC, | NA |
| 2102- | TQ, | A review on therapeutic potential of Nigella sativa: A miracle herb |
| - | Review, | Var, | NA |
| 2103- | TQ, | Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells |
| - | in-vitro, | PC, | Hs766t | - | in-vitro, | PC, | MIA PaCa-2 |
| 2105- | TQ, | Thymoquinone Promotes Pancreatic Cancer Cell Death and Reduction of Tumor Size through Combined Inhibition of Histone Deacetylation and Induction of Histone Acetylation |
| - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | Hs766t | - | in-vivo, | NA, | NA |
| 2108- | TQ, | Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of Nigella sativa |
| - | Review, | Var, | NA |
| 3407- | TQ, | Thymoquinone and its pharmacological perspective: A review |
| - | Review, | NA, | NA |
| 3425- | TQ, | Advances in research on the relationship between thymoquinone and pancreatic cancer |
| 3426- | TQ, | Thymoquinone-Induced Reactivation of Tumor Suppressor Genes in Cancer Cells Involves Epigenetic Mechanisms |
| - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | AML, | JK |
| 3422- | TQ, | Thymoquinone, as a Novel Therapeutic Candidate of Cancers |
| - | Review, | Var, | NA |
| 3423- | TQ, | Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics |
| - | Review, | Var, | NA |
| 3421- | TQ, | Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer |
| - | Analysis, | Nor, | NA | - | in-vivo, | Nor, | NA | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | HaCaT |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:140 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid